A recent study highlights the potential of nucleoside reverse transcriptase inhibitors (NRTIs), originally developed for HIV treatment, to mitigate biological aging by suppressing retrotransposon activity. Researchers investigated the effects of two NRTI combinations—emtricitabine/tenofovir-alafenamide (FTC/TAF) and emtricitabine/tenofovir-disoproxil fumarate (FTC/TDF)—on biological age markers in healthy individuals aged 18-50. The results indicated that FTC/TAF significantly reduced measures of biological aging, including DunedinPACE and PhenoAge, while FTC/TDF showed no such effects.

The significance of these findings lies in the established role of retrotransposons in aging. As individuals age, epigenetic silencing mechanisms that typically keep these elements in check deteriorate, leading to their reactivation and subsequent inflammatory responses that contribute to age-related dysfunction. The study’s results suggest that targeting retrotransposon activity through NRTIs could offer a novel therapeutic avenue to address aging-related pathologies, as evidenced by the observed declines in epigenetic markers of inflammation alongside biological age.

This research shifts the paradigm in aging interventions by providing a compelling rationale for the exploration of antiretroviral therapies as potential gerotherapeutics. The differential effects of FTC/TAF versus FTC/TDF underscore the importance of drug selection and pharmacological profiles in developing effective aging interventions. Future placebo-controlled studies integrating clinical pharmacology with direct assessments of transposable element activity and aging biomarkers are essential to validate these findings and further elucidate the mechanistic pathways involved.

Source: fightaging.org